BHPW
VRTX icon

Beverly Hills Private Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Beverly Hills Private Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-795
Closed -$271K – 330
2023
Q2 		$271K Buy
+795
New +$268K 0.04% 289

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Beverly Hills Private Wealth's VRTX Position: Q3 2023 in Review

Beverly Hills Private Wealth sold out of Vertex Pharmaceuticals (VRTX) in Q3 2023, closing a stake of 795 shares — an estimated $271K sold.

Beverly Hills Private Wealth first reported a position in VRTX in Q2 2023 and held it in 1 quarter. The position peaked at $271K in Q2 2023. 1,277 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

  • Beverly Hills Private Wealth reported no remaining Vertex Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Beverly Hills Private Wealth sold 795 Vertex Pharmaceuticals shares in Q3 2023, an estimated $271K.
  • Beverly Hills Private Wealth first reported a position in Vertex Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Beverly Hills Private Wealth's Vertex Pharmaceuticals position peaked at $271K in Q2 2023.
  • 1,277 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on Beverly Hills Private Wealth's 13F filing for Q3 2023, filed 8 Nov 2023.